Related Experiment Video

Updated: Sep 25, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase

Anca M Bulgaru1, Sridhar Mani, Sanjay Goel

  • 1Montefiore Medical Center, Department of Oncology, Bronx, NY 10467, USA. abulgaru@montefiore.org

Expert Review of Anticancer Therapy
|June 25, 2003
PubMed

Insights

Overexpression of the epidermal growth factor receptor (EGFR) is linked to poor cancer prognosis. Blocking EGFR with drugs like erlotinib shows promise in inhibiting cancer cell growth and proliferation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) overexpression correlates with poor prognosis in various human cancers.
  • Cancers with high EGFR levels exhibit resistance to conventional chemotherapy and radiation therapy.
  • EGFR represents a significant therapeutic target for cancer treatment.

Purpose of the Study:

  • To review the mechanisms by which epidermal growth factor receptor (EGFR) blockade impacts cancer cell signaling.
  • To discuss the effects of EGFR blockade on cell cycle progression, proliferation, and differentiation.
  • To examine the role of erlotinib (Tarceva) as a reversible EGFR tyrosine kinase inhibitor in cancer therapy.

Main Methods:

  • Review of scientific literature on EGFR signaling pathways and cancer.
  • Analysis of preclinical and clinical data for EGFR inhibitors, specifically erlotinib.
  • Discussion of signal transduction modulation and its downstream effects on cancer cells.

Main Results:

  • EGFR blockade alters intracellular signal transduction pathways.
  • Inhibition of EGFR leads to cell cycle arrest and reduced cancer cell proliferation.
  • Erlotinib has demonstrated promising antitumor activity in Phase II and Phase III clinical trials for solid tumors.

Conclusions:

  • Targeting the epidermal growth factor receptor (EGFR) is a validated strategy in oncology.
  • EGFR tyrosine kinase inhibitors, such as erlotinib, offer a promising therapeutic approach for managing malignancies.
  • Further clinical studies are ongoing to confirm the long-term clinical benefit of EGFR blockade.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...